{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:08:36Z","timestamp":1778692116244,"version":"3.51.4"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T00:00:00Z","timestamp":1528848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although immunosuppressants in the treatment of myasthenia have been available for several decades, population\u2010based studies describing drug utilization in myasthenia patients are scarce. We aimed in this study to describe the treatment of myasthenia in Denmark in more recent years with emphasis on use of oral immunosuppressant agents. We identified a nationwide cohort of incident myasthenia patients in Denmark from 1996 to 2013 and tracked their use of drugs over the entire period using data from nationwide registers. Patients with myasthenia were classified according to utilization of specific immunosuppressants (e.g. prednisolone) as \u2018never user\u2019 or \u2018ever user\u2019. We used Kaplan\u2013Meier (K\u2010M) and proportion of patients covered (PPC) curves to describe treatment onset and termination. We identified 928 patients (52% female) with incident myasthenia in the study period. Overall, 638 (69%) were treated with prednisolone and 506 (55%) with azathioprine. Treatment with prednisolone and azathioprine within 2\u00a0years of myasthenia diagnosis was initiated in 462 (56%) and 366 (45%). Only one of four myasthenia patients (n\u00a0=\u00a0231) did not receive oral immunosuppressive treatment at any time in the study period. Prednisolone was stopped in most patients, whereas treatment with azathioprine was often continued throughout follow\u2010up. In conclusion, we found that treatment of myasthenia in Denmark in recent years corresponded well to the expected clinical course of myasthenia and that most patients underwent long\u2010term immunosuppression.<\/jats:p>","DOI":"10.1111\/bcpt.13034","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T03:24:51Z","timestamp":1525663491000},"page":"486-493","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Oral Immunosuppressive Treatment of Myasthenia Gravis in Denmark: A Nationwide Drug Utilization Study, 1996\u20132013"],"prefix":"10.1111","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7761-4391","authenticated-orcid":false,"given":"Emil Greve","family":"Pedersen","sequence":"first","affiliation":[{"name":"Department of Neurology Odense University Hospital &amp; Department of Clinical Research Faculty of Health Sciences University of Southern Denmark (SDU) Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper","family":"Hallas","sequence":"additional","affiliation":[{"name":"Department of Public Health, Clinical Pharmacology SDU Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Potteg\u00e5rd","sequence":"additional","affiliation":[{"name":"Department of Public Health, Clinical Pharmacology SDU Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stine Munk","family":"Hald","sequence":"additional","affiliation":[{"name":"Department of Neurology Odense University Hospital &amp; Department of Clinical Research Faculty of Health Sciences University of Southern Denmark (SDU) Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poul Erik Hyldgaard","family":"Jensen","sequence":"additional","affiliation":[{"name":"Neuroimmunology Laboratory, DMSC Department of Neurology Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5205-7007","authenticated-orcid":false,"given":"David","family":"Gaist","sequence":"additional","affiliation":[{"name":"Department of Neurology Odense University Hospital &amp; Department of Clinical Research Faculty of Health Sciences University of Southern Denmark (SDU) Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,6,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70063-8"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.44"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-015-0398-y"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03019.x"},{"key":"e_1_2_7_8_1","first-page":"98","article-title":"Mestinon (Pyridostigmine bromide) in myasthenia gravis","volume":"75","author":"Schwarz H","year":"1956","journal-title":"Can Med Assoc J"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1998.tb05968.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.6.1778"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198703193161205"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12439"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12703"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2012.10.028"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2015.10.018"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S91125"},{"key":"e_1_2_7_17_1","first-page":"798","article-title":"Data resource profile: the Danish national prescription registry","volume":"46","author":"Potteg\u00e5rd A","year":"2017","journal-title":"Int J Epidemiol"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000331481"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12108"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-014-9930-3"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494810393563"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494810393562"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2012.03850.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8045-z"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12359"},{"key":"e_1_2_7_26_1","first-page":"1978","article-title":"Myasthenia gravis and Lambert\u2010Eaton myasthenic syndrome","volume":"22","author":"Nicolle MW","year":"2016","journal-title":"Contin Minneap Minn"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2015-001126"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1415"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282f51031"},{"key":"e_1_2_7_31_1","unstructured":"Danish Myasthenia Guidelines.Dan Soc Neurol. n.d.http:\/\/neuro.dk\/wordpress\/kliniske-retningslinjer\/danske-behandlingsvejledninger\/(last accessed on 31 December 2017)."},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb51317.x"},{"key":"e_1_2_7_33_1","unstructured":"RasmussenL PrattN HansenMR HallasJ Potteg\u00e5rdA.Using the \u201cProportion of Patients Covered\u201d and the Kaplan\u2010Meier Survival Analysis to describe Treatment Persistence. (Under review) n.d."}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcpt.13034","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T10:03:31Z","timestamp":1694945011000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.13034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,13]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1111\/bcpt.13034"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.13034","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,13]]},"assertion":[{"value":"2018-02-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}